Auris files for IPO

Audiology company Auris Medical AG (Zug, Switzerland) filed to raise up to $86.3 million in an IPO on NASDAQ underwritten by Jefferies; Leerink Partners; JMP Securities; and Needham. Auris' esketamine ( AM-101) is in the North American Phase III TACTT2 trial and the European Phase III TACTT3 trial for acute inner ear tinnitus, with top-line data expected in early 2016. The company has an SPA from FDA for TACTT2. In 4Q14, Auris plans to begin Phase III testing for its AM-111 to treat acute inner ear hearing loss. AM-101 is an intratympanicly injected non-competitive antagonist of NMDA receptors, and AM-111 is a selective c-jun N-terminal kinase (JNK) inhibitor. AM-111 is partnered with Xigen S.A. (Epalinges, Switzerland). ...